Biomaterials Innovation
Show Less

Biomaterials Innovation

Bundling Technologies and Life

Alexander Styhre

Rapid advances in the life sciences means that there is now a far more detailed understanding of biological systems on the cellular, molecular and genetic levels. Sited at the intersection between the life sciences, the engineering sciences and the design sciences, innovations in the biomaterials industry are expected to garner increasing attention and play a key role in future development. This book examines the biomaterials innovations taking place in corporations and in academic research settings today.
Buy Book in Print
Show Summary Details
You do not have access to this content

Chapter 6: Financing biomaterials innovation: selling science in venture capital markets

Alexander Styhre


One of the most comprehensive changes in the world economy over the last four decades is the increased emphasis on financial markets and financial actors. The so-called ‘financialization’ of the economy (Krippner, 2005, 2011; Tomaskovic-Devey and Lin, 2011; Dore, 2008; Epstein, 2005; Lapavitsas, 2012) has emerged on the basis of macroeconomic and political changes and on the basis of the increased domain of jurisdiction of economists in the field of finance theory. Today, corporations are managed by and large on the basis of their ability to satisfy the demand for shareholder value creation, that is, to optimize the value produced to the benefit of the owners of the firm. One of the principal arguments in favour of shareholder value corporate governance policy and its underlying theoretical framework, agency theory, is that capital invested wisely can be released and transferred to other, more competitive, industries and corporations (Jensen, 1993). Such alleged efficiency of operative capital is, however, not necessarily supported by empirical evidence. While Lazonick and Tulum (2011) and Pisano (2006), for example, stress the substantial inflow of capital into the US biotechnology industry during the last few decades, despite poor performance in terms of profitability and output of new therapies, such increases in venture capital have not been observed in other parts of the world.

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.